JAK inhibition with Ruxo or itacitinib (a specific JAK1 inhibitor) has been tested in patients with advanced solid tumors (NCT02646748 and NCT02646748), non–small cell lung cancer (NCT02917993 and NCT03425006), and triple-negative breast cancer (NCT02876302 and NCT03012230),15 but its utility in overcoming ICB resistance has not been assessed. This evidence concerns the gene JAK1 and triple-negative breast carcinoma.